U
EVGN icon

UBS’s Evogene EVGN Stock Holding History

UBS’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$669K Sell
5,085
-77
-1% -$10.6K ﹤0.01% 4000
2014
Q2 		$845K Sell
5,162
-81
-2% -$13.9K ﹤0.01% 3712
2014
Q1 		$999K Buy
5,243
+55
+1% +$10.4K ﹤0.01% 3488
2013
Q4 		$1.02M Buy
+5,188
New +$958K ﹤0.01% 3522

Other funds holding EVGN

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

UBS's EVGN Position: Q3 2014 in Review

UBS reduced its Evogene (EVGN) stake by 1.5% in Q3 2014, selling an estimated $10.6K and leaving 5,085 shares worth $669K. The position accounts for ﹤0.01% of the portfolio, ranked #4000.

UBS first reported a position in EVGN in Q4 2013 and has held it in 4 quarters since. The position peaked at $1.02M in Q4 2013. 15 funds tracked by Wall St. Rank hold EVGN as of Q3 2014.

  • UBS held 5,085 shares of Evogene worth $669K as of Q3 2014.
  • UBS sold 77 Evogene shares in Q3 2014, an estimated $10.6K.
  • Evogene made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4000 holding.
  • UBS first reported a position in Evogene in Q4 2013 and has held it in 4 quarters since.
  • UBS's Evogene position peaked at $1.02M in Q4 2013.
  • 15 funds tracked by Wall St. Rank held Evogene as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.